Medunik USA is dedicated to providing Americans suffering from rare diseases with access to orphan drugs that are not currently available in the U.S. We make these treatment options available by building strategic partnerships with international companies to bring their products to the American market. Through in-licensing partnerships, Medunik USA offers turn-key operations and provides medical scientific liaisons, approval and market access processes and marketing for orphan disease treatments. Medunik USA is part of the Duchesnay group, which consists of five pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. In 2009, the company launched Medunik Canada to bring orphan drugs to Canadians with rare diseases. Today, Medunik USA brings orphan drugs to the U.S. market to provide Americans with rare diseases with the life-changing and potentially life-saving treatment options they deserve.